225 related articles for article (PubMed ID: 19748231)
1. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of antimicrobial use density (AUD) of carbapenem antibacterial agents and investigation of the drug susceptibility of Pseudomonas aeruginosa in 3 hospitals in southern Ibaraki Prefecture, Japan].
Oishi T; Hitomi S; Kamoshita M; Fukue H; Kawahata D; Fukutake K
Rinsho Byori; 2008 Jul; 56(7):570-6. PubMed ID: 18709988
[TBL] [Abstract][Full Text] [Related]
3. [A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
Kakeya H; Yamada K; Nakaie K; Takizawa E; Okada Y; Fujita A; Nakamura Y; Abe J; Hirose A; Kaneko Y; Hino M
Jpn J Antibiot; 2014 Aug; 67(4):241-8. PubMed ID: 25420320
[TBL] [Abstract][Full Text] [Related]
4. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
[TBL] [Abstract][Full Text] [Related]
6. The Implementation of a Hospital-wide Practice for the Selective Use of Carbapenems Based on the Monitoring of Susceptibility of Pseudomonas aeruginosa Isolates.
Ohshima T; Asai S; Miyazawa M; Yamamoto Y; Hisada A; Kumazawa C; Hashimoto M; Fukawa K; Iwashita H; Umezawa K; Yamada S; Yamamoto Y; Miyachi H
Tokai J Exp Clin Med; 2017 Dec; 42(4):176-181. PubMed ID: 29228415
[TBL] [Abstract][Full Text] [Related]
7. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
[TBL] [Abstract][Full Text] [Related]
8. [Study on antibiotics susceptibility and mechanism of carbapenem-resistance in clinical isolates of Pseudomonas aeruginosa].
Arita K; Daido K; Ohashi N; Nakamura K; Takeshima Y; Kohara T
Jpn J Antibiot; 1999 Jul; 52(7):491-6. PubMed ID: 10516928
[TBL] [Abstract][Full Text] [Related]
9. [Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
Hikida M; Terashima S; Sato Y; Okamoato R; Inoue M
Jpn J Antibiot; 2001 Nov; 54(11):571-9. PubMed ID: 11828603
[TBL] [Abstract][Full Text] [Related]
10. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
[TBL] [Abstract][Full Text] [Related]
11. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibility to chemotherapeutics and the occurrence of metallo-beta-lactamases in hospital Pseudomonas aeruginosa strains].
Nowak P; Targosz A; Budak A; Oleksiak D; Geza G; Skałkowska M
Med Dosw Mikrobiol; 2006; 58(3):231-7. PubMed ID: 17340998
[TBL] [Abstract][Full Text] [Related]
13. Overview of a new carbapenem, panipenem/betamipron.
Shimada J; Kawahara Y
Drugs Exp Clin Res; 1994; 20(6):241-5. PubMed ID: 7758396
[TBL] [Abstract][Full Text] [Related]
14. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan.
Sanbongi Y; Shimizu A; Suzuki T; Nagaso H; Ida T; Maebashi K; Gotoh N
Microbiol Immunol; 2009 Jul; 53(7):361-7. PubMed ID: 19563394
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of doripenem.
Sahm D
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
[TBL] [Abstract][Full Text] [Related]
16. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
[TBL] [Abstract][Full Text] [Related]
17. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
[No Abstract] [Full Text] [Related]
18. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
Goyal K; Gautam V; Ray P
Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO; Mazumder SA
J Antimicrob Chemother; 2009 Jun; 63(6):1297-9. PubMed ID: 19369268
[No Abstract] [Full Text] [Related]
20. [Antimicrobial activity of carbapenem antibiotics against gram-negative bacilli].
Kinoshita S; Kumagai S
Jpn J Antibiot; 1998 Sep; 51(9):551-60. PubMed ID: 9846282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
